The DOI matches its Crossref record.
Diverse Transcriptional Response of CD4+ T Cells to Stromal Cell-Derived Factor (SDF)-1: Cell Survival Promotion and Priming Effects of SDF-1 on CD4+ T Cells
Open accessAbstract
Stromal cell-derived factor (SDF)-1 is a ligand for the chemokine receptor CXCR4 which is broadly expressed in lymphocytes, but the effects of SDF-1 on T cells are largely unknown. When examined using complementary DNA microarray, up-regulation of genes which are associated with DNA repair, detoxification, apoptosis, cell morphology, cell adhesion, and signal transduction was seen in CD4+ T cells upon SDF-1 exposure. SDF-1 was shown to promote CD4+ T cell survival through the phosphatidylinositol 3-kinase (PI3K)- and mitogen-activated protein kinase (MAPK)-cascades without cell cycle progression. The proapoptotic Bcl-2 antagonistic of cell death protein was also seen inactivated by the SDF-1-mediated activation of MAPK-extracellular signal-regulated kinases (MEK)-extracellular signal-regulated kinase-ribosomal S6 kinases- and PI3K-pathways. Moreover, the genes known to be associated with cell survival were up-regulated upon SDF-1 exposure and were linked to the MAPK-MEK and PI3K-pathways. Thus, SDF-1 promotes cell survival by two mechanisms: posttranslational inactivation of the cell death machinery and an increased transcription of cell survival-related genes. SDF-1 also primed resting CD4+ T cells for cytokine- and TCR-mediated stimuli. These data suggest that the SDF-1-mediated cell survival combined with its priming function would set T cells to respond to immunologic challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Teicher, B. A., & Fricker, S. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2329 · Cited by 1,449
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis
Phillips, R. J., Burdick, M. D., Hong, K., Lutz, M. A., Murray, L. A., Xue, Y. Y., Belperio, J. A., Keane, M. P., & Strieter, R. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420997 · Cited by 1,079
Imitola, J., Raddassi, K., Park, K. I., Mueller, F.-J., Nieto, M., Teng, Y. D., Frenkel, D., Li, J., Sidman, R. L., Walsh, C. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408258102 · Cited by 1,057
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
Rubin, J. B., Kung, A. L., Klein, R. S., Chan, J. A., Sun, Y., Schmidt, K., Kieran, M. W., Luster, A. D., & Segal, R. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235846100 · Cited by 615
Johannessen, M., Delghandi, M. P., & Moens, U. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.05.001 · Cited by 590
Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis
Darash-Yahana, M., Pikarsky, E., Abramovitch, R., Zeira, E., Pal, B., Karplus, R., Beider, K., Avniel, S., Kasem, S., Galun, E., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0935fje · Cited by 421
Chemokines: agents for the immunotherapy of cancer?
Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398
CXCR4 Is a Major Chemokine Receptor on Glioma Cells and Mediates Their Survival
Zhou, Y., Larsen, P. H., Hao, C., & Yong, V. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206222200 · Cited by 363
Hauser, A. E., Debes, G. F., Arce, S., Cassese, G., Hamann, A., Radbruch, A., & Manz, R. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1277 · Cited by 361
Marchesi, F., Monti, P., Leone, B. E., Zerbi, A., Vecchi, A., Piemonti, L., Mantovani, A., & Allavena, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1343 · Cited by 339
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Shi, Y., Riese, D. J., & Shen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574667 · Cited by 336
Robin, A. M., Zhang, Z. G., Wang, L., Zhang, R. L., Katakowski, M., Zhang, L., Wang, Y., Zhang, C., & Chopp, M. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600172 · Cited by 305
Furusato, B., Mohamed, A., Uhlén, M., & Rhim, J. S. (2010) · Pathology International · doi:10.1111/j.1440-1827.2010.02548.x · Cited by 290
Tabera, S., Perez-Simon, J. A., Diez-Campelo, M., Sanchez-Abarca, L. I., Blanco, B., Lopez, A., Benito, A., Ocio, E., Sanchez-Guijo, F. M., Canizo, C., et al. (2008) · Haematologica · doi:10.3324/haematol.12857 · Cited by 283
Lazarini, F., Tham, T. N., Casanova, P., Arenzana‐Seisdedos, F., & Dubois‐Dalcq, M. (2003) · Glia · doi:10.1002/glia.10139 · Cited by 280
Chemokines: Roles in leukocyte development, trafficking, and effector function
Ono, S. J., Nakamura, T., Miyazaki, D., Ohbayashi, M., Dawson, M., & Toda, M. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1594 · Cited by 257
Molecular and cellular basis of rheumatoid joint destruction
Karouzakis, E., Neidhart, M., Gay, R. E., & Gay, S. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.04.011 · Cited by 167
Broxmeyer, H. E., Kohli, L., Kim, C. H., Lee, Y., Mantel, C., Cooper, S., Hangoc, G., Shaheen, M., Li, X., & Clapp, D. W. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.1002495 · Cited by 162
Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity
Klein, R. S., & Rubin, J. B. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.04.002 · Cited by 132
Cinalli, R. M., Herman, C. E., Lew, B. O., Wieman, H. L., Thompson, C. B., & Rathmell, J. C. (2005) · European Journal of Immunology · doi:10.1002/eji.200425729 · Cited by 19
Metadata
- Authors
- Suzuki, Y., Rahman, M., & Mitsuya, H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-09
- Volume
- 167
- Issue
- 6
- Pages
- 3064-3073
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2104315295
- Cited by
- 176
- References
- 0
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.